Skip to main content
Clinical Trials/NCT03963700
NCT03963700
Unknown
Not Applicable

Genomic Profile and Tumor Immune Attack in Paraneoplastic Neurological Syndromes (PNS)

Hospices Civils de Lyon1 site in 1 country980 target enrollmentFebruary 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer
Sponsor
Hospices Civils de Lyon
Enrollment
980
Locations
1
Primary Endpoint
Proportion of mutations in cancer genes coding for onconeural proteins and inflammatory response mediators.
Last Updated
6 years ago

Overview

Brief Summary

Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer that can affect any part of the central or peripheral nervous system.

PNS occurs at the intersection between immune system and the tumor, where a combination of genetical and environmental factors may play a role.

Mechanisms leading to immune tolerance breakdown and autoimmunity in PNS remain largely unknown, and this reflects in an unsatisfactory repertoire of treatments available. Moreover, a better understanding of the biological mechanisms underlying PNS would allow a more precise identification of the modalities that permit PNS patients to have a better oncological prognosis than cancer patient without PNS, with obvious repercussions in clinical oncology.

To this effect, an extremely innovative approach involves directly exploring the tumoral tissue of patients suffering from specific PNS via genomic and transcriptomic analysis.

The study team hypothesizes that antigen ectopic expression by tumour cells may contribute to the generation of PNS.

In the present study, the investigators will analyze the salient features of tumors associated with PNS, namely the histological and immune cells infiltrate characteristics, their transcriptomic profile, and mutational status of involved antigens.

Registry
clinicaltrials.gov
Start Date
February 1, 2019
End Date
January 1, 2022
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • presence of well characterized antibodies in serum or cerebrospinal fluid;
  • histologically proven cancer with available tumour sample;
  • Paraneoplastic neurological syndrome (PNS) diagnosis according to the international guidelines;
  • Age: at least 18 years old.

Exclusion Criteria

  • Absence of complete clinicopathological data

Outcomes

Primary Outcomes

Proportion of mutations in cancer genes coding for onconeural proteins and inflammatory response mediators.

Time Frame: 36 months

Genetic alterations in tumors associated with Paraneoplastic neurological syndromes (PNS)

Secondary Outcomes

  • Proportion of different immune cells in the tumor's immune infiltrate(36 months)

Study Sites (1)

Loading locations...

Similar Trials